Roche Challenged the Madras High Court's Decision

The Mumbai High Court has decided to consider Valycte patent infringement case only after eight weeks based on the order of the Madras High Court. Earlier, the Madras High Court ordered the Indian Patent Office to reexamine the patent granted to Valycte active ingredient, Valganciclovir before January 31, 2009. Roche later decided to challenge the Madras High Court’s decision and has filed a special leave petition before the Supreme Court of India. In another development, the Mumbai High Court restrained Cipla from using the trademark “Valcept” for its generic version of Valycte.